Authorized Generics: Band-Aid or Strategy?
Executive Summary
In the past two years, some Big Pharma companies have revitalized their long-dormant generics activities and launched generic copies of their own drugs. They're doing this to capture business they would otherwise lose completely and to tie up generics competitors in court. While similar strategies failed in the past, a number of changes may make it more feasible. Innovators are behaving more rationally about pricing. And they are going after the most lucrative part of the generics business.
You may also be interested in...
Generic Plavix: As Bristol Swoons, Broad Implications
The immediate ramifications of Bristol and Sanofi's failed authorized generics strategy around Plavix may cripple Bristol, hobble, Sanofi, and make a mint for Canadian generics player Apotex. But the most significant impact may be felt in the long term along the fault line where branded and generics companies meet, compete, and increasingly, deal.
Mylan's War on Authorized Generics
Changes to the Medicaid law will put a crimp in the economics of "authorized" generic agreements. But Mylan won't be happy until Congress takes further action.
Teva/Ivax: Generics' Answer to Big Pharma
Bigger generics companies aren't just the generic sector's problem. Giants such as the new Teva will present more formidable challenges to innovators, not just in patent wars but also with proprietary launches, and for a share of drug consumption in developing markets.